Navigation Links
Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease

Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cyclic norethisterone--or no hormone replacement therapy. The women were followed for 4 years. Overall, 134 women received hormone replacement therapy. Of these, 58 had had a previous hysterectomy. The other 121 women served as controls.

On intention-to-treat analysis, there was no statistical difference in the incidence of unstable angina requiring hospitalization, MI or premature death from heart disease in women receiving HRT and women not receiving the therapy. Respectively, the average event rates were 15.6 and 12.6 per 100 patient-years. Results from the PHASE study also seem to indicate an increased risk of thromboembolic complications, such as stroke, with HRT. This observation is supported by results from the HERS study, a randomized trial carried out in the US that included 3000 women, and was designed to assess the cardioprotective effect of combined HRT in women with documented CAD.

It may therefore be appropriate that women with proven coronary artery disease should not commence HRT. Nevertheless, women receiving HRT for more than 2 years should continue.
'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal Vaccine Effective in Treating Alzheimers Disease in Mice
3. Transdermal HRT not cardioprotective in postmenopausal women with CAD
4. Transdermal HRT not cardioprotective in postmenopausal women with CAD
5. Enlarged waistline may predict atherogenesis for postmenopausal women
6. Research explains why postmenopausal women accumulate abdominal fat.
7. Testosterone Therapy can improve sexual function in postmenopausal women
8. Transdermal HRT not cardioprotective in postmenopausal women with CAD
9. Starvation in pregnant women can cause heart disease to their children
10. Brisk Walking lowers memory loss in women
11. Young womens woes
Post Your Comments:
(Date:7/25/2008)...ewswire-FirstCall/ -- Thoratec,Corporation (Nasdaq...l,circulatory support therapies to save, support a... will report its operating results for the second,...rsday, July 31., The company will hold a conferen...ting activities to all interested parties at 1:30 ...
(Date:7/25/2008)...nsumers tips and encourages them to, ,Speak Up,(T...July 25 /PRNewswire-USNewswire/ -- The Pennsylvani...l Patient Safety Day" which,is a national effort t...pate fully in their healthcare by asking questions...ery or illness., "We understand the important rol...
(Date:7/25/2008)...ing Exclusivity Begins -, CORONA, Calif., July 25... Inc. (NYSE: WPI ), a leading specialty pharmaceu... has commenced commercial,shipment of its Omeprazo...g,strength from its Davie, Florida manufacturing f...s 180 days of marketing exclusivity for being the,...
(Date:7/25/2008)...iance to be presented at Fenway Park ... 25 /PRNewswire/ -- CVS/pharmacy announced today,t... million in just 21 days,through its annual in-sto...the seventh year of the annual fundraising effort ...or ALS research. This year,s fundraiser took,place...
Breaking Medicine News(10 mins):Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2
...ve been killed in Turkey with the object of combat...untry. This has been revealed by the Turkish Natio...ion has been detected in as many as 13 provinces i...uspected cases. The provinces where the bird flu h...
...eing sued by four Marlboro smokers for hi-tech scr...r. The four people are demanding that the company .... //If this were to be brought into force, it will... of early detection. The company has been accused ...
... prove to be as beneficial to people suffering fro...is has been revealed by a Dutch study. The same am...tients who underwent these two therapies, when com...t at all. A combination of both the treatments did...
...nce a day for treating AIDS is sought to be develo...Gilead Sciences Inc. The regimen of three drugs wi... receive a formal approval towards end 2006. //As ...fected by AIDS, with the poor nations accounting f...
Other Medicine News:
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
(Date:7/22/2008)...ma Exhibits Excellent Drug-Like ...itiation of Phase II Clinical Trials -, RESEARCH ...x BioPharma,Inc., a clinical stage company develo... diseases of the central nervous system, today ann...TM) into Phase II trials for the,treatment of depr...
(Date:7/22/2008)...and pegylated enzyme produces significantly enh... - Pegylated enzyme well tolerated -...lozyme Therapeutics,Inc. (Nasdaq: HALO ), a biop...ng products targeting the extracellular matrix, to...nical animal efficacy data,for its pegylated-rHuPH...
(Date:7/22/2008)... Risk Based on Clinical Data, Preventive Measur...WALTHAM, Mass., July 22 /- ...nounced the launch of an enhanced test report,form... Health Genetic Test.,The test is currently market...netic Test by Quixtar/Amway. The new report will i...
Breaking Medicine Technology:Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Over 30 New Studies of Oral Xeloda 28R 29 Featured at the 2008 Gastrointestinal Cancers Symposium 1270 1Over 30 New Studies of Oral Xeloda 28R 29 Featured at the 2008 Gastrointestinal Cancers Symposium 1270 2Over 30 New Studies of Oral Xeloda 28R 29 Featured at the 2008 Gastrointestinal Cancers Symposium 1270 3Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference 2730 1U S Department of Labor Announces 241 25 Million to North Carolina to Help Trade Affected Workers Pay for Health Insurance 10083 1U S Department of Labor Announces 241 25 Million to North Carolina to Help Trade Affected Workers Pay for Health Insurance 10083 2Surprise in Lab Helps ID Drug to Fight ALS 10080 1Surprise in Lab Helps ID Drug to Fight ALS 10080 2
... Diamyd Medical AB (<a target="_blank" href=,"http...AM B;, www.otcqx.com ,ticker DMYDY) , , STOCKHOL...on,made in Linkoping, Sweden at the Sweden-Seattle... Johnny Ludvigsson, the Principal,Investigator in ...e,II study in type 1 diabetes, presented potential...
...DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos...data on the immunosuppressive,properties of solubl...g to be held in San Francisco, May 5-9. The presen...sts at the University of,Western Ontario., "These ...raft,survival in transplantation, and that it can ...
Other Medicine Technology:Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 2Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 3Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 4Revolutionary Immunologic Data Explains Function of Diamyd Diabetes,Vaccine 5Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: